Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Cross Below 200 Day Moving Average – Time to Sell?

Posted by Francis Steltz on Aug 20th, 2026

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $29.84 and traded as low as $27.30. Lakefront Biotherapeutics American Depositary Shares shares last traded at $27.99, with a volume of 329,243 shares.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LKFT. Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Royal Bank Of Canada reduced their price target on shares of Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Morgan Stanley lowered their price objective on shares of Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.67.

Get Our Latest Report on Lakefront Biotherapeutics American Depositary Shares

Lakefront Biotherapeutics American Depositary Shares Price Performance

The business has a 50 day simple moving average of $28.68 and a 200 day simple moving average of $29.81. The stock has a market cap of $1.87 billion, a PE ratio of -20.08 and a beta of 0.27.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.01. The firm had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $7.29 million. As a group, sell-side analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Madison Avenue Partners LP grew its position in Lakefront Biotherapeutics American Depositary Shares by 0.8% in the fourth quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after acquiring an additional 17,394 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 2,490.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock valued at $49,083,000 after purchasing an additional 1,362,229 shares in the last quarter. UBS Group AG raised its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% during the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock valued at $11,427,000 after purchasing an additional 196,445 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 121.9% in the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after purchasing an additional 186,452 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after purchasing an additional 115,946 shares during the last quarter. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

(Get Free Report)

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.